Compare MDWD & CMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDWD | CMT |
|---|---|---|
| Founded | 2000 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Electronic Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.7M | 185.6M |
| IPO Year | 2014 | N/A |
| Metric | MDWD | CMT |
|---|---|---|
| Price | $18.80 | $20.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $37.50 | N/A |
| AVG Volume (30 Days) | ★ 96.8K | 22.0K |
| Earning Date | 11-20-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.93 |
| Revenue | $20,932,000.00 | ★ $261,619,000.00 |
| Revenue This Year | $15.89 | N/A |
| Revenue Next Year | $25.33 | $6.66 |
| P/E Ratio | ★ N/A | $22.12 |
| Revenue Growth | ★ 6.15 | N/A |
| 52 Week Low | $14.14 | $12.25 |
| 52 Week High | $22.51 | $22.29 |
| Indicator | MDWD | CMT |
|---|---|---|
| Relative Strength Index (RSI) | 55.40 | 64.87 |
| Support Level | $18.71 | $19.78 |
| Resistance Level | $19.40 | $20.84 |
| Average True Range (ATR) | 0.63 | 0.66 |
| MACD | 0.14 | 0.22 |
| Stochastic Oscillator | 65.42 | 87.90 |
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam, and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.